Full-Time

Scientific Director

Toxicology

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Expert

Cambridge, MA, USA

70% in-office presence required.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • PhD & 10 years of scientific experience OR Master’s degree & 15 years of scientific experience OR Bachelor’s degree & 20 years of scientific experience in preclinical toxicology and drug development in the pharmaceutical/biotechnology sector.
  • Experience serving in the capacity of a Toxicology representative on drug development programs in the pharmaceutical/biotechnology industry and corresponding experience in designing and executing nonclinical safety strategies and studies to support clinical development.
  • Extensive experience in writing and reviewing nonclinical modules for regulatory submissions (e.g., multiple INDs/CTAs and preferably BLA/NDA/MAA).
  • Experience in responding to health authority queries and presenting to authorities in person or virtually.
  • Demonstrated leadership in developing regulatory toxicology/safety strategies that influence the development of programs across multiple therapeutic modalities (e.g. small molecules and biotherapeutics)
  • Experience in mentoring, coaching, and/or managing others on developing toxicology/regulatory strategies.
  • Broad knowledge of GLP regulations and ICH/FDA regulatory guidelines for the conduct of nonclinical safety studies to support regulatory filings.
  • Experience working with Contract Research Organizations.
  • Outstanding written and verbal communication skills and the ability to develop and deliver clear and concise presentations for both internal and external stakeholders.
  • Demonstrated ability to work successfully in a fast-paced and dynamic work environment, with the agility to quickly pivot in the face of new data and/or strategic directions.
  • Attention to detail and quality, and ability to deliver work on time.
Responsibilities
  • In conjunction with development program teams and a cross-functional and integrated nonclinical team, develop toxicology strategies and provide expert support to development projects, particularly those in early- and late-stage clinical development.
  • Serve as functional line representative on development program core teams and help lead cross-functional nonclinical subteams.
  • Design, execute, and critically analyze nonclinical in vitro and/or in vivo safety studies conducted in multiple species via collaborative partnerships with study monitors and other partner line program representatives (e.g., drug metabolism and pharmacokinetics [DMPK], bioanalytical, program management, study management and outsourcing, etc.).
  • Lead finalization of toxicology study reports and manage the tabular presentation of data in accordance with CTD format.
  • Review, summarize, and integrate complex datasets across all nonclinical safety disciplines (toxicology, safety pharmacology, genotoxicity, developmental & reproductive toxicology, immunotoxicology, etc) for project teams, portfolio management, senior leaders, internal/external partners and/or scientific groups.
  • Provide strategic advice to project teams and senior management including evaluation of conclusions and potential impact of toxicology results on program and clinical/regulatory strategy.
  • Apply expert knowledge when reviewing, editing, and/or authoring regulatory submissions and health authority interaction documents (e.g., briefing documents, regulatory query responses) for assigned programs and integrate results with DMPK and pharmacology. Represent toxicology and/or integrated nonclinical functions with health authorities to support early- and late-stage clinical development and marketing applications (BLA, MAA).
  • Collaborate closely with Research, Regulatory, Manufacturing, and Clinical to deliver on company objectives. Work closely with Clinical colleagues to ensure toxicology coverage for clinical trial designs and marketed product dosing regimens.
  • Collaborate with the Head of Toxicology and other partner line leaders to positively influence the department and organization.
  • Regularly operate as a leader by mentoring and having direct and/or matrix management responsibilities for other toxicology program representatives by providing scientific guidance and input and by leading by example.
  • Maintain extensive scientific awareness and presence internally and externally, leading initiatives to publish manuscripts and posters, present at scientific conferences and other scientific forums, represent Moderna on cross-company consortiums, engage with consultants and advisors in the field, as well as the scientific community at large.
  • Serve as a resource for the department and project teams, proactively keeping colleagues and leadership updated with industry trends.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for various biological functions. Their approach involves creating a new class of medicines that utilize mRNA to instruct cells to produce specific proteins, potentially leading to significant advancements in treating diseases. Unlike traditional pharmaceuticals, which often rely on small molecules or proteins, Moderna's mRNA-based therapies aim to enhance the speed and efficiency of drug discovery and manufacturing. The company's goal is to improve patient outcomes by harnessing the power of mRNA to create effective treatments for a range of health conditions.

Company Stage

IPO

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

4%

1 year growth

15%

2 year growth

48%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's AI-driven drug discovery accelerates novel mRNA-based therapeutics identification.
  • Expansion in Asia enhances global supply chain and reduces production costs.
  • mRNA technology is gaining traction for non-infectious disease vaccines, like cancer.

What critics are saying

  • Potential Nasdaq 100 removal could impact stock visibility and investor interest.
  • Bypassing safety steps in Australia may raise regulatory and public scrutiny concerns.
  • Hong Kong's reluctance to receive Covid-19 jab affects market penetration and sales.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for a new class of medicines.
  • The company focuses on mRNA's potential to transform drug discovery and manufacturing.
  • Moderna's mRNA platform enables rapid development of vaccines and therapeutics.

Help us improve and share your feedback! Did you find this helpful?